JP2015504299A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504299A5 JP2015504299A5 JP2014538724A JP2014538724A JP2015504299A5 JP 2015504299 A5 JP2015504299 A5 JP 2015504299A5 JP 2014538724 A JP2014538724 A JP 2014538724A JP 2014538724 A JP2014538724 A JP 2014538724A JP 2015504299 A5 JP2015504299 A5 JP 2015504299A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fusion
- protein
- fusion protein
- ret
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims 25
- 102000037865 fusion proteins Human genes 0.000 claims 25
- 230000004927 fusion Effects 0.000 claims 19
- 108090000623 proteins and genes Proteins 0.000 claims 17
- 108091033319 polynucleotide Proteins 0.000 claims 10
- 239000002157 polynucleotide Substances 0.000 claims 10
- 102000040430 polynucleotide Human genes 0.000 claims 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 8
- 210000000349 chromosome Anatomy 0.000 claims 8
- 201000005202 lung cancer Diseases 0.000 claims 8
- 208000020816 lung neoplasm Diseases 0.000 claims 8
- 239000000523 sample Substances 0.000 claims 8
- 101001050559 Homo sapiens Kinesin-1 heavy chain Proteins 0.000 claims 7
- 102100023422 Kinesin-1 heavy chain Human genes 0.000 claims 7
- 210000004899 c-terminal region Anatomy 0.000 claims 7
- 239000002773 nucleotide Substances 0.000 claims 7
- 125000003729 nucleotide group Chemical group 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 238000003745 diagnosis Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 108091023037 Aptamer Proteins 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000014509 gene expression Effects 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 230000008707 rearrangement Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 229940127513 Fusion Protein Inhibitors Drugs 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 229960001292 cabozantinib Drugs 0.000 claims 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 1
- 229940125874 fusion protein inhibitor Drugs 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161553483P | 2011-10-31 | 2011-10-31 | |
| US61/553,483 | 2011-10-31 | ||
| US13/663,565 | 2012-10-30 | ||
| US13/663,565 US10023855B2 (en) | 2011-10-31 | 2012-10-30 | Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker |
| PCT/KR2012/009056 WO2013066047A1 (en) | 2011-10-31 | 2012-10-31 | Fusion protein comprising c-terminal domain of ret protein and use thereof as a diagnosing marker |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015504299A JP2015504299A (ja) | 2015-02-12 |
| JP2015504299A5 true JP2015504299A5 (enExample) | 2015-12-03 |
| JP6389124B2 JP6389124B2 (ja) | 2018-09-12 |
Family
ID=48192340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014538724A Active JP6389124B2 (ja) | 2011-10-31 | 2012-10-31 | Ｒｅｔ蛋白質のｃ−末端ドメインを含む融合蛋白質及びその診断マーカーとしての用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10023855B2 (enExample) |
| EP (1) | EP2773673B1 (enExample) |
| JP (1) | JP6389124B2 (enExample) |
| KR (2) | KR101625139B1 (enExample) |
| WO (1) | WO2013066047A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013028817A1 (en) | 2011-08-23 | 2013-02-28 | Foundation Medicine , Inc. | Novel kif5b-ret fusion molecules and uses thereof |
| JP6513567B2 (ja) * | 2012-09-07 | 2019-05-15 | エクセリクシス， インク． | 肺腺癌の治療で使用するためのｍｅｔ、ｖｅｇｆｒ、およびｒｅｔの阻害剤 |
| PL2902029T3 (pl) | 2012-09-25 | 2019-01-31 | Chugai Seiyaku Kabushiki Kaisha | Inhibitor RET |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| RS65069B1 (sr) | 2015-11-02 | 2024-02-29 | Blueprint Medicines Corp | Inhibitori ret-a |
| AR107912A1 (es) | 2016-03-17 | 2018-06-28 | Blueprint Medicines Corp | Inhibidores de ret |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| EP3674325A4 (en) * | 2017-08-21 | 2021-11-03 | Taiho Pharmaceutical Co., Ltd. | FUSION PROTEIN OF DCTN1 PROTEIN WITH RET PROTEIN |
| SG11202009681YA (en) | 2018-04-03 | 2020-10-29 | Blueprint Medicines Corp | Ret inhibitor for use in treating cancer having a ret alteration |
| WO2021243192A1 (en) | 2020-05-29 | 2021-12-02 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| CR20220666A (es) | 2020-05-29 | 2023-05-05 | Blueprint Medicines Corp | Composiciones farmacéuticas de pralsetinib |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL126918A (en) | 1996-05-08 | 2007-06-03 | Biogen Idec Inc | Ret ligand (retl) for stimulating neural and renal growth |
| AU2001281136A1 (en) | 2000-08-04 | 2002-02-18 | Board Of Regents, The University Of Texas System | Detection and diagnosis of smoking related cancers |
| AU2004286845A1 (en) | 2003-10-30 | 2005-05-19 | Tufts-New England Medical Center | Prenatal diagnosis using cell-free fetal DNA in amniotic fluid |
| JPWO2007049624A1 (ja) | 2005-10-24 | 2009-04-30 | 武田薬品工業株式会社 | 癌の予防・治療剤 |
| US20110195072A1 (en) | 2006-09-12 | 2011-08-11 | Anne Boulay | Non-neuroendocrine cancer therapy |
| JPWO2012014795A1 (ja) | 2010-07-26 | 2013-09-12 | アステラス製薬株式会社 | 新規ｒｅｔ融合体の検出法 |
| WO2013018882A1 (ja) | 2011-08-04 | 2013-02-07 | 独立行政法人国立がん研究センター | Ｋｉｆ５ｂ遺伝子とｒｅｔ遺伝子との融合遺伝子、並びに該融合遺伝子を標的としたがん治療の有効性を判定する方法 |
| WO2013028817A1 (en) * | 2011-08-23 | 2013-02-28 | Foundation Medicine , Inc. | Novel kif5b-ret fusion molecules and uses thereof |
-
2012
- 2012-10-30 US US13/663,565 patent/US10023855B2/en active Active
- 2012-10-31 JP JP2014538724A patent/JP6389124B2/ja active Active
- 2012-10-31 KR KR1020147013826A patent/KR101625139B1/ko active Active
- 2012-10-31 KR KR1020167010433A patent/KR101660235B1/ko active Active
- 2012-10-31 WO PCT/KR2012/009056 patent/WO2013066047A1/en not_active Ceased
- 2012-10-31 EP EP12845116.8A patent/EP2773673B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hu et al. | Mycobacterium tuberculosis RbpA protein is a new type of transcriptional activator that stabilizes the σ A-containing RNA polymerase holoenzyme | |
| Ma et al. | The role of circular RNAs in regulating resistance to cancer immunotherapy: mechanisms and implications | |
| Malik et al. | Targeting the MLL complex in castration-resistant prostate cancer | |
| Dews et al. | Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster | |
| Lulli et al. | Mir-370-3p impairs glioblastoma stem-like cell malignancy regulating a complex interplay between HMGA2/HIF1A and the oncogenic long non-coding RNA (lncRNA) NEAT1 | |
| KR20160138494A (ko) | Fgfr 융합물 | |
| CN111630166B (zh) | 条件性-siRNA及其在治疗心肌肥大中的用途 | |
| JP2019512014A (ja) | がん診断法および治療法におけるｐｉＲＮＡを使用する組成物および方法 | |
| JP2015513529A5 (enExample) | ||
| US20210008070A1 (en) | Targeting minimal residual disease in cancer with cd36 antagonists | |
| Fasanaro et al. | ROD1 is a seedless target gene of hypoxia-induced miR-210 | |
| JP2017516458A5 (enExample) | ||
| JP2011511949A5 (enExample) | ||
| JP6755242B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| Yang et al. | Circular RNA transcriptomic analysis of primary human brain microvascular endothelial cells infected with meningitic Escherichia coli | |
| US20250116034A1 (en) | Novel methods for rapid detection of immunogenic epitopes in biothreat agents and emerging pathogens for peptide vaccines and therapeutics | |
| KR20250021325A (ko) | 유전적 동인을 조절하기 위한 조성물 및 방법 | |
| Zhang et al. | MicroRNA‐146‐5p promotes pulmonary artery endothelial cell proliferation under hypoxic conditions through regulating USP3 | |
| KR20230088634A (ko) | 간암 특이적 바이오 마커 및 이의 용도 | |
| RU2013103466A (ru) | Блокада сигнализации ccl18 через ccr6 как терапевтический способ лечения при фиброзных заболеваниях и раке | |
| Kumar et al. | t (4; 11) leukemias display addiction to MLL-AF4 but not to AF4-MLL | |
| JP2014523736A5 (enExample) | ||
| AU2022235412A1 (en) | Immune enhancers | |
| Li et al. | NUP98‐p65 complex regulates DNA repair to maintain glioblastoma stem cells | |
| US20210261966A1 (en) | TREATMENT OF CARDIOMYOPATHY THROUGH MODULATION OF HYPOXIA-INDUCED eRNA ACTIVITY |